Abstract Primary MET amplification is an infrequent tumorigenic driver gene alteration identified in pulmonary neoplasms. Data on the effectiveness of MET-tyrosine kinase inhibitor (TKI) therapy in de novo MET amplification are relatively scarce. and there remains a dearth of empirical evidence supporting the use of precision therapy as first-line treatment for advanced non-small cell... https://xrbrands.shop/